Biology of colorectal liver metastases

Surgical Oncology Clinics of North America

Volumn 12, Issue 1, 2003, Pages 135-150

  Ahmad, Syed A ^a   Berman, Russell S ^b   Ellis, Lee M ^c  

^a UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; ANGIOPOIETIN; BATIMASTAT; CETUXIMAB; CYCLOOXYGENASE 2 INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; FLUOROURACIL; FOLINIC ACID; GEFITINIB; GROWTH FACTOR; GROWTH FACTOR RECEPTOR; IRINOTECAN; MATRIX METALLOPROTEINASE; SEMAXANIB; THROMBOSPONDIN; TISSUE INHIBITOR OF METALLOPROTEINASE; VASCULOTROPIN; VASCULOTROPIN ANTIBODY;

ANGIOGENESIS; APOPTOSIS; CANCER INVASION; CELL INTERACTION; CELL MIGRATION; CELL MOTILITY; CLINICAL TRIAL; COLORECTAL CANCER; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; EXTRACELLULAR MATRIX; HUMAN; LIVER METASTASIS; NONHUMAN; REVIEW; SIDE EFFECT; TUMOR VASCULARIZATION;

CARCINOMA; CELL PHYSIOLOGY; COLORECTAL NEOPLASMS; GROWTH SUBSTANCES; HUMANS; LIVER; LIVER NEOPLASMS; MEMBRANE PROTEINS; METALLOENDOPEPTIDASES; NEOPLASTIC PROCESSES; NEOVASCULARIZATION, PATHOLOGIC;

EID: 0037264714     PISSN: 10553207     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1055-3207(02)00078-9     Document Type: Review

References (49)

1. Butler TP, Gullino P. Quantitation of cell shedding into efferent blood vessels of mammary adenocarcinoma. Cancer Res 1975;35:512.
2. Koretz K, Schlag P, Boumsell L, et al. Expression of VLA-alpha 2, VLA-alpha 6, and VLA-beta 1 chains in normal mucosa and adenomas of the colon, and in colon carcinomas and their liver metastases. Am J Pathol 1991;138:741-5.
3. Pignatelli M, Smith ME, Bodmer WF. Low expression of collagen receptors in moderate and poorly differentiated colorectal adenocarcinomas. Br J Cancer 1990;61:636-8.
4. Brooks PC, Clark RA, Cheresh DA. Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science 1994;264:569-571.
5. Raftopoulos I, Davaris P, Karatzas G, et al. Level of α-catenin expression in colorectal cancer correlates with invasiveness, metastatic potential and survival. J Surg Oncol 1998;68:92-9.
6. St-Pierre Y. Dissemination of T cell lymphoma to target organs: a post-homing event implicating ICAM-1 and matrix metalloproteinases. Leuk Lymphoma 1999;34:53.
7. Benchimol S, Fuks A, Jothy S, et al. Carcinoembryonic antigen, a human tumor marker, functions as an intercellular adhesion molecule. Cell 1989;57:327-34.
8. Jessup JM, Ishii S, Mitzoi T, et al. Carcinoembryonic antigen facilitates experimental metastasis through a mechanism that does not involve adhesion to liver cells. Clin Exp Metastasis 1999;17:481-8.
9. Tanabe KK, Ellis LM, Saya H. Expression of CD44R1 adhesion molecule in colon carcinomas and metastases. Lancet 1993;341:725-6.
10. Coulombe J, Pelletier G. Gangliosides and organ-specific metastatic colonization. Int J Cancer 1993;53:104-9.
11. x antigens. Semin Cancer Biol 1993;4:319-24.
12. Gutman M, Fidler IJ. Biology of human colon cancer metastasis. World J Surg 1995;19:226-34.
13. McCawley LJ, Matrisian LM. Matrix metalloproteinases: they're not just for matrix anymore. Curr Opin Cell Biol 2001;13:534-40.
14. Matrisian LM, Wright J, Newell K, et al. Matrix-degrading metalloproteinases in tumor progression. Princess Takamatsu Symp 1994;24:152-61.
15. Kleiner DE, Stetler-Stevenson G. Matrix metalloproteinases and metastasis. Cancer Chemother Pharmacol 1999;43:S42.
16. Masaki T, Matsuoka H, Sugiyama H, et al. Matrilysin (MMP-7) as a significant determinant of malignant potential of early invasive colorectal carcinomas. Br J Cancer 2001;10:1317-21.
17. Ogata Y, Miura K, Ohkita A, et al. Imbalance between matrix metalloproteinase 9 and tissue inhibitor of metalloproteinases 1 expression by tumor cells implicated in liver metastases from colorectal carcinoma. Kurume Med J 2001;48:211-8.
18. Levy AT, Cioce V, Sobel ME, et al. Increased expression of the Mr 72,000 type IV collagenase in human colonic adenocarcinoma. Cancer Res 1991;51:439-44.
19. Wang Y, Liang X, Wu S, et al. Inhibition of colon cancer metastases by a 3′-end antisense urokinase receptor mRNA in a nude mouse model. Int J Cancer 2001;92:257-62.
20. Hiscox SE, Hallett MB, Puntis MCA, et al. Expression of the HGF/SF receptor, c-met, and its ligand in human colorectal cancers. Cancer Invest 1997;15:513-21.
21. Fujita S, Sugano K. Expression of c-met proto-oncogene in primary colorectal cancer and liver metastases. Jpn J Clin Oncol 1997;27:378-83.
22. Di Renzo MF, Olivero M, Giacomini A, et al. Overexpression and amplification of the Met/HGF receptor gene during the progression of colorectal cancer. Clin Cancer Res 1995;1:147-54.
23. Markowitz SD, Molkentin K, Gerbic C, et al. Growth stimulation by coexpression of transforming growth factor-α and epidermal growth factor receptor in normal and adenomatous human colon epithelium. J Clin Invest 1990;86:356.
24. Grady WM, Rajput A, Myeroff L, et al. Mutation of the type II transforming growth factor-β receptor is coincident with the transformation of human colon adenomas to malignant carcinomas. Cancer Res 1998;58:3101-4.
25. Radinsky R, Risin S, Fan D, et al. Level and function of epidermal growth factor receptor predict the metastatic potential of human colon carcinoma cells. Clin Cancer Res 1995;1:19-31.
26. Parker C, Roseman BJ, Bucana CD, et al. Preferential activation of the epidermal growth factor receptor in human colon carcinoma liver metastases in nude mice. J Histochem Cytochem 1998;46:595-602.
27. Singh P, Rubin N. Insulin like growth factors and binding proteins in colon cancer. Gastroenterology 1993;105:1218-37.
28. Freier S, Weiss O, Eran M, et al. Expression of the insulin-like growth factors and their receptors in adenocarcinoma of the colon. Gut 1999;44:704-8.
29. Remacle-Bonnet MM, Garrouste FL, Heller S, et al. Insulin-like growth factor-I protects colon cancer cells from death factor-induced apoptosis by potentiating tumor necrosis factor alpha-induced mitogen-activated protein kinase and nuclear factor kappaB signaling pathways. Cancer Res 2000;60:2007-17.
30. Koenuma M, Yamori T, Tsuruo T. Insulin and insulin-like growth factor 1 stimulate proliferation of metastatic variants of colon carcinoma 26. Jpn J Cancer Res 1989;80:51-8.
31. Reinmuth N, Liu W, Fan F, et al. Blockade of insulin-like growth factor receptor-I function inhibits growth and angiogenesis of colon cancer. Clin Cancer Res 2002;10:3259-69.
32. Takahashi Y, Kitadai Y, Bucana CD, et al. Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res 1995;55:3964-8.
33. Takahashi Y, Tucker SL, Kitadai Y, et al. Vessel counts and expression of vascular endothelial growth factor as prognostic factor in node-negative colon cancer. Arch Surg 1997;132:541-6.
34. Kang SM, Maeda K, Chung YS, et al. Vascular endothelial growth factor expression correlates with hematogenous metastasis and prognosis in colorectal carcinoma. Oncol Rep 1997;4:381-4.
35. Tokunaga T, Nakamura M, Oshika Y, et al. Thrombospondin 2 expression is correlated with inhibition of angiogenesis and metastasis of colon cancer. Br J Cancer 1999;79:354-9.
36. Ahmad SA, Liu W, Jung YD, et al. Differential expression of angiopoietin-1 and -2 in human colon cancer: a possible mechanism for initiation of angiogenesis. Cancer 2001;92:1138-43.
37. Holash J, Maisonpierre PC, Compton D, et al. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 1999;284:1994-8.
38. Berman RS, Portera CA, Ellis LM. Biology of liver metastases. In: Talamonti M, editor. Liver-directed therapy for primary and metastatic liver tumors. 2001. p. 1-29
39. Frisch SM, Francis H. Disruption of epithelial cell-matrix interactions induces apoptosis. J Cell Biol 1994;124:619-26.
40. Berman RS, Sweeney B, McConkey DJ. Metastatic colorectal cancer cells are resistant to anoikis, inducing Akt phosphorylation (A2162). Proceedings of the 90th annual meeting of the American Association for Cancer Research. New Orleans (LA): American Cancer Society; 1999;40:326
41. Warren RS, Yuan H, Matli MR, et al. Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis. J Clin Invest 1995;95:1789-97.
42. Shaheen RM, Davis DW, Liu W, et al. Antiangiogenic therapy targeting the tyrosine kinase receptor for vascular endothelial growth factor receptor inhibits the growth of colon cancer liver metastasis and induces tumor and endothelial cell apoptosis. Cancer Res 1999;59:5412-6.
43. Rosen PJ, Amado R, Hecht JR, et al. A phase I/II study of SU5416 in combination with 5-FU/leucovorin in patients with metastatic colorectal cancer [abstract 5D]. Proceedings of American Society of Clinical Oncology. New Orleans (LA): ASCO Publication; 2000.
44. Watson SA, Morris TM, Robinson G, et al. Inhibition of organ invasion by the matrix metalloproteinase inhibitor batimastat (BB-94) in two human colon carcinoma metastasis models. Cancer Res 1995;55:3629-33.
45. Bramhall SR, Rosemurgy A, Brown C, et al. Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial. J Clin Oncol 2001;19:3447-55.
46. Saltz L, Rubin M, Hochster H, et al. Cetuximab (IMC-C225) plus irinotecan (CPT-11) is active in CPT-11 refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR) [abstract 7]. Proceedings of American Society of Clinical Oncology. San Francisco (CA): ASCO Publication; 2001.
47. Hammond LA, Figueroa J, Schwarzberg L, et al. Feasibility and pharmacokinetic (PK) trial of ZD1839, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFRTKI), in combination with 5-FU and LV in patients with advanced colorectal cancer [abstract 544]. Proceedings of American Society of Clinical Oncology. San Francisco (CA): ASCO Publication; 2001.
48. Chen WS, Wei SJ, Liu JM, et al. Tumor invasiveness and liver metastasis of colon cancer cells correlated with cyclooxygenase-2 (COX-2) expression and inhibited by a COX-2-selective inhibitor, etodolac. Int J Cancer 2001;91:894-9.
49. Hull MA, Fenwick SW, Chapple KS, et al. Cyclooxygenase-2 expression in colorectal cancer liver metastases. Clin Exp Metastasis 2000;18:21-7.